• 1. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 4. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 5. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugation
  Feng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenols Ortho cresols
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenols Cresols Ortho cresols

3-De(hydroxymethyl)-3-methyl Salmeterol (CAS No. 1391054-40-2): A Comprehensive Overview

3-De(hydroxymethyl)-3-methyl Salmeterol (CAS No. 1391054-40-2) is a specialized chemical compound that has garnered significant attention in pharmaceutical research and development. As a derivative of Salmeterol, this compound plays a crucial role in the study of bronchodilators and respiratory therapeutics. Its unique molecular structure, which involves the removal of a hydroxymethyl group and the introduction of a methyl group, makes it a valuable subject for researchers exploring novel drug formulations.

The chemical properties of 3-De(hydroxymethyl)-3-methyl Salmeterol are of particular interest due to its potential applications in improving drug efficacy and reducing side effects. Researchers are increasingly focusing on how modifications like those seen in this compound can enhance the pharmacokinetics and pharmacodynamics of existing medications. This aligns with current trends in precision medicine and personalized drug development, where even minor structural changes can lead to significant therapeutic improvements.

In the context of respiratory diseases, which remain a global health concern, compounds like 3-De(hydroxymethyl)-3-methyl Salmeterol are being studied for their potential to offer more targeted treatment options. The ongoing research into COPD (Chronic Obstructive Pulmonary Disease) and asthma management has highlighted the need for advanced bronchodilators with improved safety profiles. This compound's structural characteristics may contribute to addressing these needs, making it a relevant topic in contemporary pharmaceutical discussions.

The synthesis and characterization of 3-De(hydroxymethyl)-3-methyl Salmeterol involve sophisticated organic chemistry techniques. Modern analytical methods such as HPLC (High-Performance Liquid Chromatography) and NMR spectroscopy are typically employed to verify its purity and structural integrity. These quality control measures are essential, especially when the compound is intended for research purposes in drug discovery programs.

From a market perspective, the demand for specialized pharmaceutical intermediates like 3-De(hydroxymethyl)-3-methyl Salmeterol has been steadily increasing. The global push for more effective respiratory medications, coupled with advancements in drug delivery systems, has created new opportunities for compounds with unique structural features. Pharmaceutical companies and research institutions are actively seeking such molecules to expand their portfolios and develop next-generation therapies.

In laboratory settings, proper handling and storage of 3-De(hydroxymethyl)-3-methyl Salmeterol are crucial to maintain its stability and research viability. Standard protocols for handling fine chemicals should be followed, including storage in controlled environments and protection from moisture and light. These precautions ensure that the compound retains its chemical properties throughout the research lifecycle.

The future research directions for 3-De(hydroxymethyl)-3-methyl Salmeterol may include exploring its potential in combination therapies or as a template for designing new chemical entities. With the growing emphasis on structure-activity relationships in drug design, this compound's modified structure offers valuable insights for medicinal chemists. Additionally, its applications may extend beyond respiratory conditions, potentially contributing to other therapeutic areas where beta-2 adrenergic receptor modulation is beneficial.

For researchers and pharmaceutical professionals seeking detailed information about 3-De(hydroxymethyl)-3-methyl Salmeterol, comprehensive analytical data and purity specifications are typically available from specialized chemical suppliers. These technical documents are essential for proper experimental design and regulatory compliance in research applications.

As the pharmaceutical industry continues to evolve, compounds like 3-De(hydroxymethyl)-3-methyl Salmeterol (CAS No. 1391054-40-2) will likely play an increasingly important role in drug discovery and development. Their ability to serve as building blocks for innovative therapies makes them valuable assets in the quest for improved medical treatments and better patient outcomes.

• 94749-11-8(4-Hydroxy-α1-6-(3-phenylpropoxy)hexylaminomethyl-1,3-benzenedimethanol)
• 89365-50-4(Salmeterol)
• 135293-13-9(2''-O-Rhamnosylicariside II)
• 108928-81-0(4-Hydroxy-a1-6-(1-methyl-3-phenylpropoxy)hexylaminomethyl-1,3-benzenedimethanol (Salmeterol Impurity))
• 94749-02-7(4-Hydroxy-a1-6-(2-phenylethoxy)hexylaminomethyl-1,3-benzenedimethanol)
• 1391051-88-9(Salmeterol Dimer Impurity (Mixture of Diastereomers))
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)